AACCE Investments
ScreenerStocksIndicesPicksETFsBlogPricing

© 2026 ACCE Investments. All rights reserved.

ACCE Investments - Institutional-grade stock research for retail investors | BetaList
IndicesStocksETFsScreenerBlogGlossaryCompareMarket dataAdvisors
TermsPrivacyCookiesDisclaimerLegal noticeProfessional termsAboutContact
VIMAB.ST

Vimab Group AB (publ) (VIMAB.ST) fair value

Industrials · Consulting Services · Nasdaq Stockholm · Sweden
kr 2.59-0.38%
Market cap kr 123MNext earnings 2025-08-28Updated Oct 22, 2026
Our verdict
Trades 70% below our fair value
Price
kr 2.59
Model fair valueConfidence: low
about kr 8.60
Built from weaker models, sales multiples or analyst targets, so treat it as a rough guide.
Not used by alerts or posts.
Valued as a loss-making company: Sales comps.
ACCE opinionVimab Group AB (publ) (VIMAB.ST)
Fair value
Not available
ACCE price target
kr 2.30
Rating
Not rated
Horizon
12 months
ACCE price target published on 23 Oct 2026, 01:52 CEST.
Price used: kr 2.59 at the close on 23 Oct 2026, 17:30 CEST.
Models: Sales comps.
Fair value: the average of the applicable valuation models (discounted cash flow, multiples, residual income, dividend discount, shareholder yield), each run on the latest financial statements and the market price shown. Opinion columns (fair value, target, rating) are shown apart from the data. Full methodology: acceinvestments.com/data/how-we-value-stocks
Full methodology
Conflicts of interest: The author holds no personal position in this security. General statement
Produced by ACCE Investments (acceinvestments.com)
Data
ACCE score
42
out of 100
1-year return
-55.7%
Dividend yield
0.00%

Vimab Group AB (publ) in four questions

Plain answers, details below
Free accounts get 5 full stock pages a month, including the four answers.
OverviewAsk ACCEValuationQualityAnalystsSmart MoneyCompareNews and Record

Overview

ACCE thesis

Vimab Group is a small Swedish consulting business with a market cap of about 124M SEK, operating in industrial services. The data I have shows revenue growing 15.5% alongside a 14.5% gross margin and a negative 4.0% operating margin, so growth is not yet translating into profit. The ROE figure of roughly -42,000% reflects a near-zero or negative equity base and should be read as a balance sheet signal, not a return metric. I don't have the product detail, competitive position or catalyst information needed to judge whether this is a structural tailwind, so that work would need to come from the company's filings and management. The one number that makes it worth a look is the combination of double-digit top-line growth with an operating loss, which points to either an early scaling phase or a cost base that has not yet caught up with the revenue.

AI-assisted·How I use AIWritten Oct 23, 2026

Walk me through this stock

Plain-English pros, cons, and what to watch. Pro feature.

PRO

Ask ACCE

Valuation

INVESTOR
Where VIMAB.ST's valuation models land
Price
kr 2.59
Model fair valueConfidence: low
about kr 8.60
Model
Fair value
Upside
Sales comps
Create a free account: 5 full stock pages a month, no card.

See what each model says, the assumptions behind it, the bad, normal and good cases, and why the fair value changed.

Quality

INVESTOR
Quality and conviction INVESTOR FEATURE

The full quality picture: a reason under every score, how the scores moved, and the conviction breakdown.

  • +A plain reason under every score
  • +Conviction breakdown and growth / value / quality / momentum scores
  • +Score history: how each score moved over time

Analysts

Wall Street consensus

No analyst coverage yet.
Analyst intelligence INVESTOR FEATURE

The full analyst picture: the price-target distribution against the current price, forward consensus estimates, and how ACCE's own models compare.

  • +Price-target low / average / high vs the current price, with implied upside
  • +Forward revenue and EPS consensus by fiscal year
  • +ACCE fair-value models lined up against the Street

Smart Money

PRO

In one line

Trades are only made public after a delay. We show the delay so you know how old the news is.

Company insiders
No trades filed
Last 90 days
Congress
No trades filed
Last 180 days
Average delay
No trades filed
From trade to public filing
Do politicians beat the market? Our backtest →
Smart money tracking PRO FEATURE

Follow the informed money: 13F position changes, insider and Congress trades, and 13D activist filings.

  • +Quarter-over-quarter institutional position changes
  • +Every insider and Congress trade, with how late it was disclosed
  • +Active 13D activist filings and top holders

Compare

Where it sits vs peers

News and Record

Recent performance

1 week
+0.0%
1 month
-30.0%
3 months
-20.3%
6 months
+12.1%
YTD
-36.8%
1 year
-55.7%

Recommendation history, last 12 months

DateTypeNewPreviousPrice
23 Oct 2026, 01:52 CESTACCE price targetkr 2.30first publicationkr 2.60

This analysis is not personalised investment advice and does not take your situation, objectives or risk tolerance into account. ACCE Investments is not an authorised investment firm.

Investing in shares carries a risk of losing capital. The value of an investment can go down as well as up.

This security trades in SEK. Exchange-rate movements can increase or reduce the result in your own currency.

Valuation horizon: 12 months from the publication date.

Conflicts of interest. ACCE Investments is operated by Adrien Chantreuil, who may hold personal positions in the securities analysed. Positions are declared on each security. ACCE receives no payment from the companies analysed or from any intermediary for this analysis.

Get the full VIMAB.ST page, free

Every model, the scenarios, fair value history, AI notes and the four questions. 5 full stock pages every month on the free plan, no card.

Free accounts get 5 full stock pages a month, including the full page.

Snapshot

Growth52Value41Quality27Momentum46Total42
Valuation
Trailing P/E
no data
Forward P/E
no data
PEG
no data
P/B
35.35x
EV / Revenue
0.8x
Book value/sh
kr 0.10
Enterprise value
kr 259M
Profitability
ROE
-42327.0%
FCF yield
-22.77%
ROIC
no data
Health and risk
Debt / equity
0.59
Dividend yield
0.00%
Beta
-1.20

Price

-53.4% · 1Y

Ask anything about VIMAB.ST

Answered from Vimab Group AB (publ) fundamentals + recent valuations. Every number shows its source and date.

This stock Peer Peer median weaker → stronger
ROEbetter than 0% of peers
low -42327%-42327%high 18%
Div yieldbetter than 100% of peers
low 0.0%0.0%high 0.0%

Peers

Prices Oct 23, 2026
CompanyPriceFair valuevs fair valueP/EROEQualityScore
VIMAB.ST Vimab Group AB (publ)kr 2.59----42327.0%2742
GRNQ Greenpro Capital Corp. Common Stock$7.80----26.7%4725
FOFO Hang Feng Technology Innovation Co. Ltd. Ordinary Shares$2.01----169.2%3119
RYOJ rYojbaba Co. Ltd. Common Shares$2.31--231.0x2.8%3330
AERT Aeries Technology Inc. Class A Ordinary Share$6.11--14.2x18.1%5670
BRILL.ST Brilliant Future AB (publ)kr 3.30kr 539% below--27.4%3137
INTJ Intelligent Group Limited Class A Ordinary Shares $3.19----19.5%5252

Sector report card

Where VIMAB.ST ranks against its sector peers on each metric.

Computing percentiles…